Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569770 | 0.83 | CYP19A1 (0.34) | SLC2A1CYP19A1TBXAS1HSP90AA1HSP90AB1 | |
| SCHEMBL3706703 | 0.79 | L3MBTL1 (0.41) | TBXAS1 | |
| SCHEMBL3969618 | 0.71 | NCF1 (0.49) | SLC2A1 | |
| SCHEMBL5959744 | 0.71 | HTR6 (0.46) | SLC2A1CYP19A1KLKB1KLK1 | |
| SCHEMBL4056966 | 0.68 | HTR6 (0.60) | SLC2A1CYP19A1KLKB1KLK1 | |
| SCHEMBL29880153 | 0.68 | HTR6 (0.60) | SLC2A1CYP19A1KLKB1KLK1 | |
| SCHEMBL3698821 | 0.68 | L3MBTL1 (0.36) | SLC2A1HSP90AA1HSP90AB1KLKB1KLK1 | |
| SCHEMBL913801 | 0.66 | MPO (0.44) | CYP19A1TBXAS1 | |
| SCHEMBL20850931 | 0.65 | HTR6 (0.40) | SLC2A1KLKB1KLK1 | |
| SCHEMBL28271849 | 0.64 | HTR6 (0.52) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | SLC2A1 3190/4885CYP19A1 2563/4885TBXAS1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.